MELINTA THERAPEUTICS INC.

Open:	-
Change:	-
Volume:	-

Low:	-
High:	-
High / Low range:	-

Type:	Stocks
Ticker:	MLNT
ISIN:

MELINTA THERAPEUTICS INC. overview

MELINTA THERAPEUTICS INC. > News Business Wire published a news.

Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis • • Business Wire • Stocks • More MELINTA THERAPEUTICS INC. news...

Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Melinta Therapeutics, LLC today announced that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over a decade. “The FDA approval of REZZAYO represents a significant milestone for Cidara,...

Thank you

MELINTA THERAPEUTICS INC. > News Business Wire published a news.

Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis • • Business Wire • Stocks • More MELINTA THERAPEUTICS INC. news...

Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Melinta Therapeutics, LLC today announced that the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee voted favorably 14 to 1 that Cidara, as part of its New Drug Application (NDA), provided sufficient evidence supporting a favorable benefit-risk assessment for a limited use indication for rezafungin for the treatment of candidemia and invasive candidiasis in adult patients with limited or no alternative treatment options....

Thank you

MELINTA THERAPEUTICS INC. > News Business Wire published a news.

Melinta Therapeutics and Hikma Sign Exclusive Licensing Agreement for Two Novel Anti-Infectives for the Middle East and North Africa Region • • Business Wire • Stocks • More MELINTA THERAPEUTICS INC. news...

Melinta Therapeutics (Melinta) and Hikma Pharmaceuticals PLC (Hikma) today announced they have entered into an exclusive licensing agreement for Vabomere ® (meropenem and vaborbactam) and Orbactiv ® (oritavancin), two novel anti-infective injectable products, for the Middle East and North Africa (MENA) region. In the United States, Orbactiv ® is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections due to designated susceptible Gram-positive...

Thank you

MELINTA THERAPEUTICS INC. > News Business Wire published a news.

Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals • • Business Wire • Stocks • More MELINTA THERAPEUTICS INC. news...

Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ to treat serious and life-threatening infections, today announced that it has entered into a definitive merger agreement with Melinta Therapeutics, Inc. (“Melinta”), pursuant to which Melinta would acquire Tetraphase, through a tender offer, for an aggregate of $39.0 million in cash, plus an additional $16.0 million in cash potentially payable under...

Thank you

MELINTA THERAPEUTICS INC. > News ClayTrader posted a new video.